MX2022005029A - Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. - Google Patents
Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.Info
- Publication number
- MX2022005029A MX2022005029A MX2022005029A MX2022005029A MX2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- mace
- sodium
- methods
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005029A true MX2022005029A (es) | 2022-07-12 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005029A MX2022005029A (es) | 2019-11-05 | 2020-11-04 | Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. |
Country Status (18)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| EP4236957A4 (en) * | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| WO2022155303A1 (en) * | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| KR20110135411A (ko) | 2009-03-27 | 2011-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CN106075451A (zh) | 2009-05-27 | 2016-11-09 | 阿斯利康(瑞典)有限公司 | 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法 |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
| BR112016003584A8 (pt) | 2013-08-21 | 2018-01-30 | Resverlogix Corp | composições farmaceuticas e uso das mesmas para regressão de placa acelerada |
| KR20160043118A (ko) | 2013-08-21 | 2016-04-20 | 리스버로직스 코퍼레이션 | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| MA43037A (fr) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
| JP6849804B2 (ja) | 2016-12-09 | 2021-03-31 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途 |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| US12551484B2 (en) | 2019-11-05 | 2026-02-17 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| KR20220124736A (ko) | 2020-01-08 | 2022-09-14 | 리스버로직스 코퍼레이션 | Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법 |
| AU2021368618B2 (en) | 2020-10-30 | 2025-02-27 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| EP4236957A4 (en) | 2020-10-30 | 2024-08-07 | Resverlogix Corp. | METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR |
-
2020
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 IL IL292696A patent/IL292696B2/en unknown
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI867086B (zh) | 2024-12-21 |
| CN114650824A (zh) | 2022-06-21 |
| US12551484B2 (en) | 2026-02-17 |
| EP4054584A4 (en) | 2023-11-08 |
| TW202131924A (zh) | 2021-09-01 |
| KR20220098757A (ko) | 2022-07-12 |
| IL292696B2 (en) | 2026-05-01 |
| CA3160147A1 (en) | 2021-05-14 |
| IL292696B1 (en) | 2026-01-01 |
| KR102935008B1 (ko) | 2026-03-09 |
| EP4054584A1 (en) | 2022-09-14 |
| JP7502811B2 (ja) | 2024-06-19 |
| IL292696A (en) | 2022-07-01 |
| US20220370452A1 (en) | 2022-11-24 |
| ES3042146T3 (en) | 2025-11-18 |
| DK4054584T3 (en) | 2025-09-01 |
| FI4054584T3 (fi) | 2025-08-22 |
| HUE073043T2 (hu) | 2025-12-28 |
| AU2020377539A1 (en) | 2022-05-19 |
| JP2023500685A (ja) | 2023-01-10 |
| BR112022008223A2 (pt) | 2022-09-06 |
| PL4054584T3 (pl) | 2025-11-03 |
| EP4054584B1 (en) | 2025-07-09 |
| PT4054584T (pt) | 2025-07-16 |
| WO2021090061A1 (en) | 2021-05-14 |
| AU2020377539B2 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550107A1 (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| EP4353317A3 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| BR112022008223A2 (pt) | Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2 | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| ZA202406651B (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| MX2021005740A (es) | Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo. | |
| TW200639159A (en) | Treatment of pain | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| EA201290827A1 (ru) | Офтальмологический раствор для лечения глазной инфекции, содержащий левофлоксацин или его соль или сольват этих соединений, способ лечения глазной инфекции, левофлоксацин или его соль или сольват этих соединений и их применение | |
| MX2023004671A (es) | Metodos para mejorar la funcion renal con una combinacion de un inhibidor del bromodominio y dominio extraterminal (bet) y un inhibidor del transporte de la glucosa dependiente del sodio 2. | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| WO2019241641A3 (en) | Cancer treatment methods | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
| WO2021015294A3 (en) | Combination therapy for cancer treatment | |
| EA202191415A1 (ru) | Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака |